By Ben Glickman
Coherus BioSciences received approval from the FDA for its on-body injector of Udenyca late Tuesday. The approval of the new presentation of Coherus’s cancer drug was previously delayed due to issues with a third-party filler. Shares rise 34%, to $2.93, after-hours.
Altisource Asset Management named William Erbey, former chairman of the company and a longtime executive at Ocwen Financial, as its next CEO and chairman. Altisource has faced series of executive resignations, including the recent departure of operating chief and interim CEO Danya Sawyer earlier this month. Shares rise 14%, to $4.80, after-hours.
Write to Ben Glickman at [email protected]
Read the full article here